Andreas Agathangelidis, PhD, Center for Research and Technology Hellas, Thermi, Greece, discusses the future directions of chronic lymphocytic leukemia (CLL) research. New technologies, such as next-generation sequencing (NGS), allow more information to be available to understand the mechanisms of pathogenesis and find novel biomarkers to better assess prognosis. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.
